Analysis of prognostic factors in patients with newly diagnosed diffuse large B-cell lymphoma and skeletal involvement

BMC Cancer

Research Article

Isabelle Krämer¹  Anthony D. Ho¹  Mathias Witzens-Harig¹  Nicola Lehners¹  Maral Saadati²  Axel Benner² 

[1] Department of Hematology and Oncology, University of Heidelberg, Im Neuenheimer Feld 410, 69120, Heidelberg, Germany;Division of Biostatistics, German Cancer Research Center, Im Neuenheimer Feld 280, 69120, Heidelberg, Germany;

关键词: Diffuse large B-cell lymphoma;    Bone disease;    Prognosis;    Risk factors;    Radiotherapy;   

DOI  :  10.1186/s12885-017-3113-z

 received in 2016-05-29, accepted in 2017-02-04,  发布年份 2017

来源: Springer

【 摘 要 】

BackgroundSkeletal involvement (SI) is observed at low prevalence in patients with diffuse large B-cell lymphoma (DLBCL). Due to the rareness of this particular condition, prospective trials for these patients are scarce.MethodsWe analyzed clinical characteristics and outcome of 75 patients with DLBCL and SI in order to identify factors with prognostic impact towards progression-free survival (PFS) and overall survival (OS).ResultsLimited stage disease (Ann Arbor stage IE-IIE) was present in 34 patients (45%), 41 patients (55%) had advanced stage disease (Ann Arbor stage IIIE-IVE). Outcome was generally favorable for patients with DLBCL and SI with 3-year OS of 83%. The international prognostic index (IPI) was able to distinguish between different risk groups within this specific entity. Additionally, hypercalcemia showed to be a factor significantly associated with inferior survival. In regard to first-line treatment modalities, consolidative radiotherapy was positively associated with prolonged PFS and OS while intensification of chemotherapy had no significant impact.ConclusionsIn our cohort of patients with DLBCL and SI, high-risk IPI as well as presence of hypercalcemia were associated with inferior outcome. Consolidative radiotherapy had a positive impact on survival.

【 授权许可】

CC BY   
© The Author(s). 2017